Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Anti-Glutamic Acid Decarboxylase Auto Antibody Associated Neurological Disorder in Patient with ALL Treated with Standard Protocol

Case Report Sample Work

To describe two examples of anti-GAD antibodies linked to neurological disorders in ALL patients who underwent normal chemotherapy treatments. To provide Clinical presentation and intervention, Pubrica Case studies demonstrate the decision-making process, allowing other physicians to apply lateral thinking to their own cases.

Two leukaemia patients, one unexpected autoantibody

This sample is a two-patient case report describing neurological illness associated with antibodies against glutamic acid decarboxylase (anti-GAD) in young people receiving treatment for acute leukaemia. Guillain-Barré syndrome during leukaemia chemotherapy has been described before, but, as the introduction notes, reports involving anti-GAD antibodies are few. By setting two different patients side by side, the report shows how the same antibody can accompany central and peripheral nervous system involvement in quite different clinical settings.

The intended readers are paediatric haemato-oncologists, neurologists and transplant physicians who may meet similar patients and need to decide quickly whether new weakness reflects drug toxicity, infection or an immune process.

Untangling drug toxicity, infection and autoimmunity

Neurological complications during leukaemia therapy have several possible sources, and the sample frames them from the outset: neurotoxicity of chemotherapeutic agents, infection, and an abnormal immune response with autoantibody production. GAD is the enzyme that synthesises the inhibitory neurotransmitter GABA, and anti-GAD antibodies have been linked in the literature to motor neuropathy and some forms of encephalopathy, classically without sensory involvement.

The discussion works through each competing explanation. Vincristine neurotoxicity is considered for the first patient. For the second, tacrolimus neurotoxicity is weighed and judged unlikely because drug levels stayed within the therapeutic range, renal function was normal and symptoms progressed after the drug was stopped. Fludarabine neurotoxicity is also considered and set aside. The authors add that demonstrating autoantibodies in the CSF, and to a lesser extent in serum, helps to support an autoimmune cause, which explains why the second case, with antibodies in serum only, is presented with more caution. This stepwise reasoning is the part of the report most likely to help another clinician facing an uncertain diagnosis.

How the two case narratives are laid out

Case 1 describes a 17-year-old male diagnosed with T-cell/myeloid mixed-phenotype acute leukaemia. After a difficult induction phase he developed weakness of the limbs and neck with partial abducens and facial nerve deficits and absent ankle reflexes, while sensation remained intact. CSF protein was raised at 233 mg/dL, nerve conduction studies showed a predominantly axonal motor neuropathy, and anti-GAD antibodies were found in the CSF. Vincristine was withheld, and his weakness resolved after intravenous immunoglobulin (IVIG). Germline sequencing in an observational study later identified one copy of a pathogenic ERCC2 variant.

Case 2 describes a girl with relapsed B-cell ALL who developed progressive weakness, swallowing difficulty and dysarthria. GAD65 antibodies were raised in serum but not CSF, and MRI showed white matter changes. Around the time of her stem cell transplant she worsened despite IVIG, improved after high-dose methylprednisolone and plasmapheresis were added, and later received rituximab for rising EBV titres. When plasmapheresis was reduced, antibody levels and symptoms rose again.

Each case follows the same order (presentation, examination, investigations, treatment, course), which lets readers compare the two directly.

Reporting a two-patient series under CARE

The CARE guidelines apply to short case series as well as single cases, and Pubrica's overview of CARE requirements for case reports sets out the full checklist. This sample reflects several CARE items: a timeline of treatment changes, the specific diagnostic tests performed (including negative results such as absent oligoclonal bands and normal NMDA receptor and VGKC-complex antibodies), dosing for key interventions, and follow-up extending over several years.

The sample also shows de-identification in practice. Author names, institution and one patient's age are left as placeholders, a reminder that personal details should be reviewed before submission and that consent for publication must be documented. Authors may also consider whether month-level dates are necessary or whether relative timings would serve equally well. References use a numbered IEEE-style format, which can be converted to Vancouver if the target journal requires it.

Lessons for writing up rare treatment-related neurological events

Two features make this report a useful template. First, it describes a treatment escalation pathway, from IVIG to steroids and plasmapheresis and then rituximab, and connects each step to the patient's response. Second, its discussion acknowledges uncertainty: the ERCC2 finding is offered as a possible predisposing factor rather than a proven cause, and the authors state that they are unaware of comparable published cases.

Clinicians preparing a similar report can use Pubrica's case report writing support to structure the narrative, or a clinical literature review to locate prior reports of anti-GAD syndromes in cancer patients. This page shows a writing sample and is not medical advice.

Questions about this sample

What do anti-GAD antibodies have to do with leukaemia treatment?

Anti-GAD antibodies target an enzyme involved in producing the neurotransmitter GABA and have been associated with motor neuropathy and encephalopathy. This sample describes two patients receiving leukaemia therapy who developed neurological illness with these antibodies, suggesting an immune process alongside, or instead of, direct drug toxicity.

Why does the report mention an ERCC2 gene variant in the first patient?

ERCC2 is a DNA repair gene. The authors suggest that impaired DNA repair, combined with oxidative stress from chemotherapy, might have predisposed the patient to autoimmune neurological illness. They present this as a possibility only, noting that they found no previously reported case of ERCC heterozygosity in this setting.

How did treatment differ between the two cases?

The first patient improved fully after a five-day course of IVIG once vincristine was withheld. The second worsened despite IVIG and required high-dose methylprednisolone and plasmapheresis, later followed by rituximab. Her antibody levels and symptoms rose again when plasmapheresis was reduced, so it was tapered slowly over two years.

Can a report with two patients still be called a case report?

Yes. Many journals accept reports of two or three related patients under the case report or short case series category. The CARE checklist still applies, and each patient should be described with the same structure so readers can compare presentation, investigations, treatment and outcome directly.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.